The news release includes forward-looking statements about Conavi's future growth and commercialization plans, highlighting potential risks and uncertainties. The company emphasizes that actual results may differ from these projections due to various factors, including the ability to retain key personnel and execute business strategies. Conavi disclaims any obligation to update these statements, advising investors to consider these risks carefully.
Key takeaways:
- Conavi Medical Corp. will present at the MedInvest MedTech, AI & Digital Health Conference on December 11, 2024, marking its first investor event as a public company.
- The company's CEO, Thomas Looby, will provide a business update during a live webcast presentation at 3:35 p.m. ET in New York City.
- Conavi Medical focuses on imaging technologies for minimally invasive cardiovascular procedures, with its Novasight Hybrid™ System combining intravascular ultrasound and optical coherence tomography.
- The Novasight Hybrid System has received regulatory approvals from the U.S. FDA, Health Canada, China's National Medical Products Administration, and Japan's Ministry of Health, Labor and Welfare.